Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity

A LLerena, P Dorado, EM Peñas-Lledó - Pharmacogenomics, 2009 - Taylor & Francis
Debrisoquine hydroxylation polymorphism is by far the most thoroughly studied genetic
polymorphism of the CYP2D6 drug-metabolizing enzyme. Debrisoquine hydroxylation …
被引用次数：93 相关文章

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity

A LLerena - Pharmacogenomics, 2009 - search.proquest.com
Debrisoquine hydroxylation polymorphism is by far the most thoroughly studied genetic
polymorphism of the CYP2D6 drug-metabolizing enzyme. Debrisoquine hydroxylation …
[PDF] researchgate.net

[PDF][PDF] Drug Focus

A LLerena, P Dorado, EM Peñas-Lledó - Pharmacogenomics, 2009 - researchgate.net
Debrisoquine hydroxylation polymorphism is by far the most thoroughly studied genetic
polymorphism of the CYP2D6 drug-metabolizing enzyme. Debrisoquine hydroxylation …

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.

A Llerena, P Dorado, EM Peñas-Lledó - Pharmacogenomics, 2009 - europepmc.org
Debrisoquine hydroxylation polymorphism is by far the most thoroughly studied genetic
polymorphism of the CYP2D6 drug-metabolizing enzyme. Debrisoquine hydroxylation …

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity

A Llerena, P Dorado… - …, 2009 - pubmed.ncbi.nlm.nih.gov
Debrisoquine hydroxylation polymorphism is by far the most thoroughly studied genetic
polymorphism of the CYP2D6 drug-metabolizing enzyme. Debrisoquine hydroxylation …

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity

A LLerena, P Dorado, EM Peñas-Lledó - Pharmacogenomics, 2009 - cir.nii.ac.jp
抄録< jats: p> Debrisoquine hydroxylation polymorphism is by far the most thoroughly
studied genetic polymorphism of the CYP2D6 drug-metabolizing enzyme. Debrisoquine …